Previous close | 30.69 |
Open | 51.04 |
Bid | 47.70 |
Ask | 52.70 |
Strike | 1,120.00 |
Expiry date | 2024-11-15 |
Day's range | 51.04 - 51.04 |
Contract range | N/A |
Volume | |
Open interest | 12 |
Key Insights The projected fair value for Regeneron Pharmaceuticals is US$1,936 based on 2 Stage Free Cash Flow to...
Regeneron (REGN) maintains momentum on the back of Dupixent profits and efforts to develop oncology portfolio despite near-term challenges.
At 14-months median follow-up in the pivotal trial, 50% of patients achieved a complete response or better and a 71% overall response rate, as presented in an EHA oral presentation and simultaneously published in the Journal of Clinical Oncology Also presented at EHA, a retrospective study of patient outcomes that compared investigational linvoseltamab to real-world standard-of-care treatment in clinical practice TARRYTOWN, N.Y., June 16, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc.